Eris delivers 10% YoY growth in DBF business and 11% in consolidated revenue during Q3 FY26

Eris Lifesciences Limited ("Eris Lifesciences" or the "Company") (BSE: 540596; NSE: ERIS), a leading Indian branded formulations manufacturing company, today announced its earnings for the quarter and nine months ended December 31, 2025.

Q3 and 9M FY2026 Key Financial Highlights:

- The DBF business reported revenue growth of 10% YoY in Q3 FY26 and 9M FY26

- Consolidated Revenue grew 11% YoY during Q3 and 8.4% YoY 9M FY26

- Consol EBITDA was Rs. 282 Cr in Q3, margin of 34.9% and Rs. 847 Cr with a margin of 35.7% during 9M FY26

- Adjusted PAT* was Rs. 120 Cr in Q3 FY26, a PAT margin of 14.9%. For 9M FY26, Adj PAT* was Rs. 380 Cr, with a 16.0% margin

- Net debt as of December 30, 2025, stood at Rs. 2,270 Cr

Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, said, "I am pleased to share that, as per our expectation, we have reached a 25% share in the RHI cartridges market in Dec-25. Eris now services one in every four Indian patients on RHI cartridges. We are well on track to achieve a dominant position in the overall Insulins market including Glargine and several analogues. We are gearing up for our GLP-1 launch in due course and are also launching Esaxerenone, a potential game changer in hypertension management, thereby strengthening our cardiovascular franchise."

Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer added, "Our core Domestic Branded Formulations business is tracking to deliver a 12% revenue growth in FY26 with a 37% EBIDTA margin. Our capital investments in Injectables, Insulins, MABs and GLP-1 in-sourcing continue in line with our guidance. We have strong visibility on FY27 shaping up as a breakout year for our international business with significant contribution expected from our CDMO clients in regulated markets."

Shares of Eris Lifesciences Limited was last trading in BSE at Rs. 1414.65 as compared to the previous close of Rs. 1511.05. The total number of shares traded during the day was 10419 in over 1187 trades.

The stock hit an intraday high of Rs. 1511.15 and intraday low of 1399.85. The net turnover during the day was Rs. 15108645.00.

Source : Equity Bulls

Keywords

ErisLifesciences INE406M01024 Pharmaceuticals Q3FY26 Q3FY2026 9MFY26 9MFY2026 ResultUpdate